Roche has launched what it says is a first-of-its-kind handheld glucose management device, backed up by a digital platform that aims to simplify the work of doctors and nurses as they deliv
Merck & Co's Keytruda is the undisputed market leader in immunotherapy for non-small cell lung cancer (NSCLC), but was leapfrogged by Roche's Tecentriq in the early-stage, adjuvant trea
Roche's idiopathic pulmonary fibrosis (IPF) therapy Esbriet is already being squeezed by its main rival in the market, and could come under renewed pressure if another competitor from PureT
